) .
Letters to Editor
Imiquimod-induced vitiligo-like Imiquimod-induced vitiligo-like depigmentation depigmentation
Sir, Imiquimod, an imidazoquinoline amine, is a potent topical immune response modifier. [1] It has been used effectively to treat human papillomavirus-induced warts, molluscum contagiosum, actinic keratoses and superficial basal cell carcinoma. [2] A 32 year-old man presented to our clinic with genital warts, which had been present for the last six months. Dermatologic examination revealed multiple verrucous papules on the shaft of the penis and pubic area and depigmented macules on the glans penis, the shaft of the penis and the scrotum [ Figure  1 ]. Imiquimod 5% cream had been applied to the warts every other night. After two months, he had noticed erythematous lesions on the dorsal surface of the penis and the scrotum. These lesions turned into depigmented areas in three months. Depigmentation never extended to the areas that had not been treated with imiquimod. No repigmentation was noted in a six-month follow-up period. The patient had no personal or family history of vitiligo.
Imiquimod is generally a well-tolerated drug. Its most frequent side effects are erythema, flaking, scabbing, edema and excoriation. In addition, only two cases of depigmentation caused by imiquimod have been reported. [3, 4] The authors speculated that imiquimod might have acted as a triggering factor in a susceptible patient who had a positive family history of vitiligo. [4] They also suggested that clinicians should be cautious when prescribing imiquimod in patients with a personal of family history of vitiligo. [4] However, our patient and the other reported case had no personal or family history of vitiligo.
Imiquimod enhances antigen presentation by stimulating CD8+ T cell activation and inducing Langerhans cell maturation. [5] Vitiligo-like depigmentation may result from the destruction of melanocytes by CD8+ T cells directed to melanocyte surface antigens after antigen presentation is enhanced by imiquimod.
Dermatologists should be aware of this possible side effect of imiquimod, which may be long-lasting or irreversible.
Successful use of imiquimod 5% Successful use of imiquimod 5% cream in Bowen's disease cream in Bowen's disease Sir, Bowen's disease is a rare, persistent, progressive intraepidermal carcinoma, which may be potentially malignant, with up to 3 cm, on the right thigh [ Figure 1 ]. It had not responded to topical steroids, salicylic acid, coal tar, retinoids or tacrolimus. With a differential diagnosis of Bowen's disease and lupus vulgaris, a skin biopsy was done and it revealed the features of Bowen's disease [ Figure 2 ]. He was started with 5% topical imiquimod, which was applied to the plaque on three alternate days in a week, with monthly follow-up. The lesion progressively decreased in size and thickness at each followup. At the three-months' follow-up, the lesion had totally flattened with persisting hyperpigmentation. A repeat biopsy at this stage revealed a normal epidermis. Imiquimod was stopped and the patient was advised follow-up every three months. After six months, the lesion had completely cleared with atrophy and pigmentation [ Figure 3 ] and a third biopsy done at this stage was also clear [ Figure 4 ]. The patient is still under follow-up at six monthly intervals, but there has been no recurrence of the lesion at the end of one year. 8% of the cases progressing to squamous cell carcinoma. The various treatment modalities include physical destruction using electrocautery, cryotherapy, curettage, laser therapy or surgical excision, intralesional interferon alpha or bleomycin and noninvasive methods like photodynamic therapy and topical 5-fluorouracil. Most of these therapies are administered by the physician, rather than being selfadministered. Imiquimod is a topical immune response modifier with antitumor and antiviral activity. Its utility in Bowen's disease, including penile, facial, vulvar, truncal and recurrent nail disease has been reported by many authors.
Here we report its successful use in an Indian patient with Bowen's disease.
A 45 year-old male factory worker presented to us with a persistent, occasionally itchy, progressively enlarging psoriasiform plaque of six months' duration measuring 5 x
Letters to the Editor Imiquimod is a potent antiviral and antitumor agent, approved by the US FDA as a topical agent in the treatment of genital and perianal warts. [1] It was later found to be beneficial in a number of cutaneous disorders including many viral infections and malignant as well as premalignant conditions, including Bowen's disease.
In a phase II trial by Mackenzie-Wood et al, the first open labeled study evaluating the use of imiquimod in Bowen's disease, a once daily application of 5% imiquimod for 16 weeks was found to be effective in 14 out of 15 patients. [2] In a randomized, double-blind, placebo-controlled trial involving 34 patients with Bowen's disease, out of 15 patients who were treated with imiquimod 5% cream, 11 achieved resolution of their lesions with no relapse during a follow-up period of nine months. [3] A phase II, randomized, doubleblind, vehicle-controlled trial involving 129 patients with histologically proven basal cell carcinoma gave complete response rates of 100, 87.1, 80.8 and 51.7% for patients in twice daily, once daily, five times a week and 3 times a week dosage schedules of 5% imiquimod, respectively. [4] Various regimes of topical treatment of cutaneous malignancies with imiquimod include alternate nights to twice daily application from a minimum of six weeks to a maximum of 20 weeks. [2] [3] [4] The more frequent the application, the greater the chance for application site reactions, which occur at a frequency of 1% and include pruritus, burning, soreness, erythema, scabbing, flaking, erosion, crusting, edema and induration, which are usually mild-moderate and are dosedependent. A thrice weekly regime is recommended in most studies because it is the least aggressive treatment which gives the greatest success rate, nearly approaching 100%.
We preferred imiquimod 5% cream over other modalities of treatment because of the easy availability, ease of self administration, lack of pain, and lack of need for hospitalization and the encouraging reports published in the last few years.
Malassezia furfur Malassezia furfur onychomycosis onychomycosis in an immunosuppressed liver in an immunosuppressed liver transplant recipient transplant recipient
Sir, It has been asserted that Malassezia spp. may be associated with seborrheic dermatitis, pityriasis versicolor, atopic dermatitis, psoriasis and confluent and reticular papillomatosis. [1] It is debatable whether Malassezia spp. is a real onychomycosis agent or a colonizer. In the literature, there are limited number of reports of onychomycosis cases in which Malassezia spp. is claimed as the agent. [2, 3] Malassezia furfur (M. furfur) isolated in toe nails of a liver transplant patient is presented here.
A 55 year-old male patient consulted us with a complaint of thickness in his toe nails for three months. The patient had had no previous onychomycosis treatment. He was undergoing therapy with multiple immunosuppressive agents for a liver transplant that he had undergone a year ago because of Hepatitis B virus (HBV)-related liver cirrhosis. In the examination of the toe nails, distal-lateral subungual hyperkeratosis and brown discoloration were detected in all of his toe nails. Periungual skin was normal [ Figure 1 ]. His skin and finger nails were normal.
Alcohol was used to remove the normal flora before the nail scrapings were taken. A cluster of yeast cells and short irregular hyphae were observed in the direct microscopic examination. They were incubated in Sabouraud and modified Dixon agar at 31 º C for two weeks. The colonies that were grown showed round and spherical spore groups and short hyphae [ Figure 2 ]. They were also incubated in Tween 20-80. The organism, Malassezia furfur was identified by its morphological features and physiological tests, including
